Resonance Health Ltd is pleased to announce an upgrade in its FY26 underlying EBITDA guidance to approximately $2.6 million, reflecting strong operational performance and margin expansion. While revenue is now expected to be around $16.0 million due to timing issues with a clinical trial agreement, the focus on higher-margin activities and cost efficiencies is driving this profitability increase. The Company's strategy of focusing on clinical trial services and disciplined cost control has led to an improved EBITDA margin of approximately 16.3%.

Key drivers of this upgrade include contributions from the SaMD segment, TrialsWest investigator site network, Resonance Clinical services, and automation improvements. Despite the revenue adjustment, operational efficiencies are expected to drive a more robust profitability outcome. Resonance Health is well-positioned for sustained growth with a diversified business model, strong revenue base, expansion opportunities, and investments in technology.

Investors are encouraged to visit our website for further information and to reach out with any questions. Our commitment to scientific rigour and quality has allowed us to gain regulatory clearances for a range of innovative products, positioning us as a leader in healthcare technology and services. We look forward to continuing our growth trajectory and delivering value to our stakeholders.